hatte die mal letztes jahr im september auf WL gesetzt, sind dann aber aufgrund des kursverlaufs, in den tiefen meiner favoriten verschwunden, leider..... :(
chart.yahoo.com/c/3m/i/imnr.gif" style="max-width:560px" >
ja ja ja, ist schon wieder deutlich überverkauft, ich weiß.... aber nur im moment!
hier alle infos: finance.yahoo.com/q?s=IMNR&d=c&k=c1&a=v&p=s&t=3m&l=on&z=m&q=l
schaut euch mal dort die quartalszahlen an, sooo übel waren die nicht....
news von heute:
Monday May 21, 7:00 am Eastern Time (BRIEFING.COM)
Press Release
SOURCE: Immune Response Corporation
Immunization With an HIV-1 Immunogen (REMUNE(TM)) Appears To Induce Allo-Responses and HIV-1 Specific Responses
Data Presented at the Federation of Clinical Immunology Societies (FOCIS) 1st Annual Meeting in Boston, Massachusetts May 4-7, 2001
CARLSBAD, Calif., May 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today data from preliminary interim clinical results from an ongoing Phase II trial indicating that treatment with REMUNE(TM) (HIV-1 Immunogen), an investigational product, appears to induce both allo and HIV specific cell mediated immune responses. Allo (allo-geneic) immune responses are directed to Human Leukocyte Antigens (HLA) and are associated with development of both CD4+ T helper and CD8+ Cytotoxic T cell (CTL) immune responses. Recently other researchers have proposed allo-antigen immunization as an additional strategy for HIV-1 vaccination. Professor Eduardo Fernandez- Cruz, M.D., Ph.D., Head of the Department of Clinical Immunology at the University General Hospital ``Gregorio Maranon'' in Madrid, Spain and Principal Investigator in the study STIR 2102 trial of REMUNE in Spain, presented data at the Federation of Clinical Immunology Societies (FOCIS) 1st Annual Meeting in Boston, Massachusetts (published in Clinical Immunology, Volume 99, April 2001).
The data analyzed a subset of 66 HIV-infected patients from a double blind, adjuvant controlled, randomized Phase II trial of REMUNE (STIR 2102) conducted in Spain. The 243 patient trial is designed to evaluate the effectiveness of REMUNE in conjunction with antiretroviral drugs on viral load and CD4 cells, which are the primary endpoints. The trial is being conducted at 13 clinical centers throughout Spain and is scheduled to end in the second quarter of 2001.
Patients treated with REMUNE plus antiretrovirals appeared to exhibit both humoral (allo-antibodies) and cell mediated (CD4+ T helper and CD8+ Cytotoxic T cell) allo-immune responses. In the REMUNE treated group, 74% (25/34) of the patients exhibited anti-HLA antibodies (an allo-immune response), compared to only 25% (8/32) of the patients who received placebo (p
ja ja ja, ist schon wieder deutlich überverkauft, ich weiß.... aber nur im moment!
hier alle infos: finance.yahoo.com/q?s=IMNR&d=c&k=c1&a=v&p=s&t=3m&l=on&z=m&q=l
schaut euch mal dort die quartalszahlen an, sooo übel waren die nicht....
news von heute:
Monday May 21, 7:00 am Eastern Time (BRIEFING.COM)
Press Release
SOURCE: Immune Response Corporation
Immunization With an HIV-1 Immunogen (REMUNE(TM)) Appears To Induce Allo-Responses and HIV-1 Specific Responses
Data Presented at the Federation of Clinical Immunology Societies (FOCIS) 1st Annual Meeting in Boston, Massachusetts May 4-7, 2001
CARLSBAD, Calif., May 21 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today data from preliminary interim clinical results from an ongoing Phase II trial indicating that treatment with REMUNE(TM) (HIV-1 Immunogen), an investigational product, appears to induce both allo and HIV specific cell mediated immune responses. Allo (allo-geneic) immune responses are directed to Human Leukocyte Antigens (HLA) and are associated with development of both CD4+ T helper and CD8+ Cytotoxic T cell (CTL) immune responses. Recently other researchers have proposed allo-antigen immunization as an additional strategy for HIV-1 vaccination. Professor Eduardo Fernandez- Cruz, M.D., Ph.D., Head of the Department of Clinical Immunology at the University General Hospital ``Gregorio Maranon'' in Madrid, Spain and Principal Investigator in the study STIR 2102 trial of REMUNE in Spain, presented data at the Federation of Clinical Immunology Societies (FOCIS) 1st Annual Meeting in Boston, Massachusetts (published in Clinical Immunology, Volume 99, April 2001).
The data analyzed a subset of 66 HIV-infected patients from a double blind, adjuvant controlled, randomized Phase II trial of REMUNE (STIR 2102) conducted in Spain. The 243 patient trial is designed to evaluate the effectiveness of REMUNE in conjunction with antiretroviral drugs on viral load and CD4 cells, which are the primary endpoints. The trial is being conducted at 13 clinical centers throughout Spain and is scheduled to end in the second quarter of 2001.
Patients treated with REMUNE plus antiretrovirals appeared to exhibit both humoral (allo-antibodies) and cell mediated (CD4+ T helper and CD8+ Cytotoxic T cell) allo-immune responses. In the REMUNE treated group, 74% (25/34) of the patients exhibited anti-HLA antibodies (an allo-immune response), compared to only 25% (8/32) of the patients who received placebo (p
